Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Conmed (CNMD) Other financing activities (2016 - 2025)

Historic Other financing activities for Conmed (CNMD) over the last 15 years, with Q2 2025 value amounting to $3.4 million.

  • Conmed's Other financing activities rose 48554.01% to $3.4 million in Q2 2025 from the same period last year, while for Dec 2025 it was $2.9 million, marking a year-over-year increase of 225.91%. This contributed to the annual value of $2.9 million for FY2025, which is 225.91% up from last year.
  • Latest data reveals that Conmed reported Other financing activities of $3.4 million as of Q2 2025, which was up 48554.01% from -$464000.0 recorded in Q1 2025.
  • Conmed's 5-year Other financing activities high stood at $15.0 million for Q2 2022, and its period low was -$5.0 million during Q3 2021.
  • Over the past 5 years, Conmed's median Other financing activities value was $2.0 million (recorded in 2024), while the average stood at $3.2 million.
  • In the last 5 years, Conmed's Other financing activities skyrocketed by 629523.81% in 2021 and then tumbled by 79253.73% in 2025.
  • Quarter analysis of 5 years shows Conmed's Other financing activities stood at $5.3 million in 2021, then tumbled by 87.76% to $643000.0 in 2022, then skyrocketed by 94.4% to $1.2 million in 2023, then tumbled by 83.6% to $205000.0 in 2024, then skyrocketed by 1539.51% to $3.4 million in 2025.
  • Its Other financing activities stands at $3.4 million for Q2 2025, versus -$464000.0 for Q1 2025 and $205000.0 for Q4 2024.